Asset Purchase Partnering Terms & Agreements Examined in New Research Report by CurrentPartnering
15 Jan 2013 • by Natalie Aster
Comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies are provided in the new report “Asset Purchase Terms & Agreements” by CurrentPartnering. The report provides a detailed understanding and analysis of how and why companies enter asset purchase deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
Asset Purchase Terms & Agreements
Published: December, 2012
Price: US$ 2,695.00
This report contains a comprehensive listing of all asset purchase deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
More information can be found in the report “Asset Purchase Terms & Agreements” by CurrentPartnering.
To order the report or ask for sample pages contact [email protected]